Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Jeil Pharmaceutical Co. Ltd. (271980) Stock Price & Analysis

271980 Stock Chart & Stats

₩8,600.00-₩230.00(-2.60%)
At close: 3:30 PM GMT+9
KRW 9,000KRW 10,000KRW 11,0003 Aug18 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
KRW 8,480.00 - KRW 8,830.00
52-Week Range
KRW 8,480.00 - KRW 19,290.00
Previous Close
KRW 8,830.00
Volume
N/A
Average Volume (3M)
15.65K
Market Cap
KRW 125.32B
Enterprise Value
KRW 242.45B
Total Cash (Recent Filing)
KRW 67.41B
Total Debt (Recent Filing)
KRW 112.28B
Price to Earnings (P/E)
7.1
Beta
0.19
Next Earnings
Nov 12, 2026 (Est.)
EPS Estimate
N/A
Last Dividend Ex-Date
Dec 27, 2023
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Profitability Recovery

The return to positive net income after losses in 2021–2024 indicates that the business has regained an earnings base. A gross margin near 39% provides room to support operating investment and sustain profitability if cost and product-mix pressures remain controlled.

Moderate Leverage

Moderate leverage gives Jeil Pharmaceutical more financial flexibility than a highly indebted structure would provide. The company is better positioned to absorb operating volatility, fund ongoing pharmaceutical activities, and manage obligations without excessive balance-sheet strain.

Balance-Sheet Stability

Relatively stable equity alongside multi-year asset growth suggests the company has maintained a substantive operating base while expanding its resources. This supports continuity of its pharmaceutical platform and provides a foundation for future commercialization and development activity.

Bears Say

Weak Cash Conversion

Negative free cash flow and repeated periods of negative operating cash flow indicate that reported earnings have not consistently converted into usable cash. This can constrain internally funded investment, increase liquidity sensitivity, and reduce resilience during weaker operating periods.

Revenue Volatility

Volatile revenue growth makes future earnings less predictable and complicates planning for pharmaceutical investment and commercialization. A rebound after a decline is encouraging, but inconsistent top-line performance can limit operating leverage and make sustained profit improvement harder to establish.

Operating Margin Pressure

The decline in operating margin shows that stronger gross profitability has not translated fully into operating earnings. If costs remain elevated or pricing and product mix weaken, the narrower margin cushion could limit profit growth and increase sensitivity to revenue fluctuations.

271980 FAQ

What was Jeil Pharmaceutical Co. Ltd.’s price range in the past 12 months?
Jeil Pharmaceutical Co. Ltd. lowest stock price was ₩8480.00 and its highest was ₩19290.00 in the past 12 months.
What is Jeil Pharmaceutical Co. Ltd.’s market cap?
Jeil Pharmaceutical Co. Ltd.’s market cap is ₩125.32B.
When is Jeil Pharmaceutical Co. Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Jeil Pharmaceutical Co. Ltd.’s earnings last quarter?
Jeil Pharmaceutical Co. Ltd. released its earnings results on Aug 14, 2026. The company reported -₩545.232 earnings per share for the quarter.
Is Jeil Pharmaceutical Co. Ltd. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Jeil Pharmaceutical Co. Ltd. pay dividends?
Jeil Pharmaceutical Co. Ltd. pays a ― dividend of ₩50 which represents an annual dividend yield of ―. See more information on Jeil Pharmaceutical Co. Ltd. dividends here
What is Jeil Pharmaceutical Co. Ltd.’s EPS estimate?
Jeil Pharmaceutical Co. Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Jeil Pharmaceutical Co. Ltd. have?
Jeil Pharmaceutical Co. Ltd. has 14,704,872 shares outstanding.
What happened to Jeil Pharmaceutical Co. Ltd.’s price movement after its last earnings report?
Jeil Pharmaceutical Co. Ltd. reported an EPS of -₩545.232 in its last earnings report. Following the earnings report the stock price went down -1.564%.
Which hedge fund is a major shareholder of Jeil Pharmaceutical Co. Ltd.?
Currently, no hedge funds are holding shares in KR:271980
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology